Can a Plant-Based pill soothe radiation side effects in prostate cancer?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male subjects aged ≥ 18 years. * Men with histologically proven localized prostate adenocarcinoma, stage I - III (as defined by American Joint Committee on Cancer (AJCC) 8th edition), who have selected treatment with brachytherapy with or without external beam radiation, with or without androgen deprivation therapy. * Fluent in speaking and reading English. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1. * Adequate organ function as defined as: * Hepatic: * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN) * aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × institutional ULN * Renal: * Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula: * Males: ((140-age)×weight\[kg\])/(serum creatinine \[mg/dL\]×72) * Highly effective contraception for both male and their female partners of childbearing potential throughout the study and for at least 5 days after last study treatment administration if the risk of conception exists. * Median life expectancy ≥ 5 years as calculated by the Lee and Schonberg Index (https://eprognosis.ucsf.edu/leeschonberg.php) * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: * Baseline AUA symptom scores \> 15. * Prior diagnosis of chronic prostatitis type II through IV. * Subject has received systemic therapy intended for the treatment of prostatitis (including herbal supplements) ≤ 14 days of starting study treatment. * Subject has received a fluoroquinolone antibiotic (e.g. ciprofloxacin, norfloxacin, ofloxacin levofloxacin, etc.) ≤ 3 days of starting study treatment. * Subject is actively on anti-inflammatory medications for other medical conditions, unless approved by PI. * Subject has undergone transurethral resection of the prostate (TURP). * Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen. * History of irritable bowel syndrome, chronic fatigue syndrome, fibromyalgia, and interstitial cystitis-bladder pain syndrome (IC/BPS). * History of symptomatic hypotension, falls, or syncope * History of hypoglycemia. * Actively abusing alcohol or drugs * Subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: * Congestive heart failure * Diabetes * Pulmonary artery hypertension * Any clinically significant condition that requires therapy with diuretic medications for any indication other than the management of hypertension. * Other clinically significant disorders that would, in the opinion of the treating investigator, preclude safe study participation. * Known prior severe hypersensitivity to investigational product or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3). * Known allergy to pineapple or pineapple containing products. * Subjects taking prohibited medications as described in Section 7.3 A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur prior to the start of treatment.